Polyneuron Pharmaceuticals

Polyneuron develops a promising new drug class to treat autoimmune disorders of the nervous system with unprecedented efficacy and safety.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Basel, Switzerland
  • Currency CHF
  • Founded November 2014
  • Employees 6
  • Incorporation Type Other
  • Website polyneuron.com

Company Summary

Polyneuron develops a promising new class of immunomodulatory drugs by virtue of its proprietary Antibody-Catch® technology platform. Platform-derived compounds selectively eliminate disease-causing autoantibodies in autoimmune disorders. The company’s lead candidate PN-1007 (anti-MAG neuropathy), will be brought into clinical trials as fast as possible. Both, the platform and PN-1007 are valuable assets for a future trade sale.

Team

  • Ruben Herrendorff
    CEO

    - Pharmaceutical scientist with specialization in neuromuscular disorders
    - Business development expertise
    - Fund-raising (grants, venture capital)
    - Team management

  • Pascal Hänggi
    CSO

    - Pharmaceutical scientist with specialization in physiology and molecular medicine
    - Bench-to-bedside expertise
    - Planning and conducting clinical trials
    - Drug regulatory affairs know-how

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free